NCT/Study#

MK3475-B96

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (KEYNOTE-B96 / ENGOT-ov65)

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus
Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of
Platinum-resistant Recurrent Ovarian Cancer (KEYNOTE-B96 / ENGOT-ov65)

DISEASE GROUP:
Gynecologic
current phase:
Phase III
STUDY STATUS:
Active
Location:
Hackensack, NJ
For More information: